Pediatric HIV infection has been successfully transformed from a universally fatal infection of childhood to a manageable chronic disease requiring a lifetime of efficacious, tolerable and safe ART. The Primary Therapy Scientific Committee’s (PTSC) agenda aims to optimize antiretroviral management of children from infancy through adolescence and into young adulthood. A major emphasis of the PTSC work is to determine the efficacy, safety, tolerance, pharmacokinetics (PK) and drug: drug interactions of existing and novel ARV agents and formulations alone and in combination across the pediatric age and developmental spectrum. 

Increasingly, pharmacokinetic studies of new formulations and new drugs are enrolling participants from IMPAACT sites in Africa, Asia, North and South America. Therapeutic and strategy trials are now designed to provide findings that will inform treatment practices and guidelines throughout the world.